Global Gene Therapy On Cardiovascular Disease Market Growth (Status and Outlook) 2023-2029

Global Gene Therapy On Cardiovascular Disease Market Growth (Status and Outlook) 2023-2029

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
LPI (LP Information)' newest research report, the “Gene Therapy On Cardiovascular Disease Industry Forecast” looks at past sales and reviews total world Gene Therapy On Cardiovascular Disease sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy On Cardiovascular Disease sales for 2023 through 2029. With Gene Therapy On Cardiovascular Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy On Cardiovascular Disease industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy On Cardiovascular Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy On Cardiovascular Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy On Cardiovascular Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy On Cardiovascular Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy On Cardiovascular Disease.
The global Gene Therapy On Cardiovascular Disease market size is projected to grow from US$ 13 million in 2022 to US$ 1334.4 million in 2029; it is expected to grow at a CAGR of 94.4% from 2023 to 2029.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy On Cardiovascular Disease market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Viral Gene Therapy
Non-Viral Gene Therapy
Segmentation by application
Heart Disease
Vascular Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute

Please note: The report will take approximately 2 business days to prepare and deliver.